Search

Vivian C Georgousis

from Wayne, NJ
Age ~59
Get Report
Also known as:
Vivan Georgousis, Vivan Georgouis
Related to:
Stravoula Georgousis, 95Stavroula Georgousis, 95Christos GeorgousisMaureen A Davison, 80Theodore Georgousis, 61Claire C Davison, 49
Connected to:
Athena Georgotas, 72Christos Georgoulas, 64Penelope Georgoudis, 50Vicky V Georgoulis, 68Mary L Georgy, 38Nahed I Georgy, 57Norkin Georgy, 42Andrew F Geosits, 71Joseph S Geosits, 84Krisztina M Geosits, 41

Vivian Georgousis Phones & Addresses

  • Wayne, NJ
  • 105 Roseland Ave, Caldwell, NJ 07006 (973) 403-7926
  • 105 Roseland Ave UNIT 1604, Caldwell, NJ 07006 (973) 403-7926
  • 27 Park St, Caldwell, NJ 07006 (973) 226-8425 (973) 403-7926 (973) 403-8978
  • West Caldwell, NJ
  • Provincetown, MA
  • 250 Ridgedale Ave, Florham Park, NJ 07932 (973) 377-4999
  • 61 Watchung Ave, Montclair, NJ 07043 (973) 746-0977
  • 250 Ridgedale Ave APT A1, Florham Park, NJ 07932 (973) 377-4999

Work

Position: Private Household Service Occupations

Resumes

Resumes

Vivian Georgousis Photo 1

Global Program Executive Director, Cardio Renal Metabolism

View page
Location:
105 Roseland Ave, Caldwell, NJ 07006
Industry:
Pharmaceuticals
Work:
Novartis
Global Program Executive Director, Cardio Renal Metabolism
Novartis Oncology Sep 2006 - Sep 2008
Medical Science Liaison
Sandoz 1991 - 1995
Senior Scientist
Education:
Long Island University 1993 - 2006
Doctorates, Doctor of Philosophy Rutgers University 1982 - 1987
Skills:
Oncology
Pharmaceuticals
Formulation Development
Program Management
Formulation
Clinical Development
Pharmaceutical Industry
Pharmaceutics
Drug Development
Medical Affairs
Clinical Trials
Regulatory Affairs
Therapeutic Areas
Gcp
Gmp
Ctms
Pharmacovigilance
Regulatory Submissions
Biotechnology
Medical Writing
Vivian Georgousis Photo 2

Vivian Georgousis

View page
Location:
New York, NY
Industry:
Pharmaceuticals

Publications

Us Patents

Liquid Formulations

View page
US Patent:
20080194526, Aug 14, 2008
Filed:
Aug 8, 2006
Appl. No.:
11/997909
Inventors:
Vivian Georgousis - West Caldwell NJ, US
Wei-Qin Tong - Basking Ridge NJ, US
International Classification:
A61K 31/66
A61K 31/131
A61P 37/00
US Classification:
514114, 514663
Abstract:
Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.

Liquid Formulations

View page
US Patent:
20120328664, Dec 27, 2012
Filed:
Sep 7, 2012
Appl. No.:
13/606118
Inventors:
Vivian Georgousis - West Caldwell NJ, US
Wei-Qin Tong - Basking Ridge NJ, US
International Classification:
A61K 47/10
A61P 37/06
A61K 31/137
US Classification:
4242781, 514772, 514653
Abstract:
Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.

Pharmaceutical Composition Comprising 5-Methyl-2(2'-Chloro-6'-Fluoroanilino)Phenylacetic Acid

View page
US Patent:
20070123593, May 31, 2007
Filed:
Oct 7, 2004
Appl. No.:
10/574537
Inventors:
Rose-Marie Dannenfelser - Bloomfield NJ, US
Vivian Georgousis - West Caldwell NJ, US
Maha Khaled - Livington NJ, US
Tarun Patel - Parsippany NJ, US
Joseph Sikora - Succasunna NJ, US
Barbara Wang - Berkeley Heights NJ, US
International Classification:
A61K 31/135
US Classification:
514650000
Abstract:
The invention relates to a composition for the treatment of a cyclooxygenase-2-mediated disorder or condition comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof suitable for parenteral administration, and to a method for the treatment of a cyclooxygenase-2-mediated disorder or condition in a human or animal in need of such treatment by parenteral administration of 5-methyl-2-(2′-chloro-6′-fluroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof.

Liquid Formulations

View page
US Patent:
20160030572, Feb 4, 2016
Filed:
Oct 15, 2015
Appl. No.:
14/883729
Inventors:
Vivian GEORGOUSIS - West Caldwell NJ, US
Wei-Qin Tong - Basking Ridge NJ, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 47/10
A61K 9/00
A61K 31/137
Abstract:
Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.

Liquid Formulations

View page
US Patent:
20150080347, Mar 19, 2015
Filed:
Dec 6, 2013
Appl. No.:
14/099072
Inventors:
Vivian Georgousis - West Caldwell NJ, US
Wei-Qin Tong - Basking Ridge NJ, US
Assignee:
NOVARTIS AG - Basel
International Classification:
C07F 9/141
C07D 205/04
C07C 215/28
US Classification:
514114, 514646, 51421017
Abstract:
Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.
Control profile
Vivian C Georgousis from Wayne, NJ, age ~59 Get Report